Share-based Payment Arrangement, Expense of Climb Bio, Inc. from 30 Jun 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Climb Bio, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2020 to 30 Sep 2025.
  • Climb Bio, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,976,000, a 36% increase year-over-year.
  • Climb Bio, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $8,669,000, a 70% increase year-over-year.
  • Climb Bio, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $5,557,000, a 57% decline from 2023.
  • Climb Bio, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $12,806,000, a 83% increase from 2022.
  • Climb Bio, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $6,991,000, a 87% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Climb Bio, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $8,669,000 $3,976,000 +$1,054,000 +36% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $7,615,000 $1,013,000 +$501,000 +98% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $7,114,000 $2,022,000 +$1,557,000 +335% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $5,557,000 $1,658,000 +$456,000 +38% 01 Oct 2024 31 Dec 2024 10-K 25 Mar 2025 2024 FY
Q3 2024 $5,101,000 $2,922,000 +$2,266,000 +345% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $2,835,000 $512,000 -$265,000 -34% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $3,100,000 $465,000 -$9,706,000 -95% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $12,806,000 $1,202,000 -$693,000 -37% 01 Oct 2023 31 Dec 2023 10-K 25 Mar 2025 2024 FY
Q3 2023 $13,499,000 $656,000 -$1,127,000 -63% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $14,626,000 $777,000 -$995,000 -56% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $15,621,000 $10,171,000 +$8,630,000 +560% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $6,991,000 $1,895,000 +$741,000 +64% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $6,250,000 $1,783,000 +$547,000 +44% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $5,703,000 $1,772,000 +$722,000 +69% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $4,981,000 $1,541,000 +$1,244,000 +419% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $3,737,000 $1,154,000 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2023 2022 FY
Q3 2021 $1,236,000 +$1,187,000 +2422% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $1,050,000 +$999,000 +1959% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $297,000 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q3 2020 $49,000 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 $51,000 01 Apr 2020 30 Jun 2020 10-Q 13 Sep 2021 2021 Q2

Climb Bio, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $5,557,000 -$7,249,000 -57% 01 Jan 2024 31 Dec 2024 10-K 25 Mar 2025 2024 FY
2023 $12,806,000 +$5,815,000 +83% 01 Jan 2023 31 Dec 2023 10-K 25 Mar 2025 2024 FY
2022 $6,991,000 +$3,254,000 +87% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $3,737,000 +$3,030,000 +429% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2023 2022 FY
2020 $707,000 01 Jan 2020 31 Dec 2020 10-K 07 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.